SCN2A encodes the alpha-subunit of voltage-gated sodium channel, Nav1.2, which is highly expressed at an early stage of the postnatal brain. Genetic studies revealed that de novo heterozygous mutations of SCN2A caused severe developmental disorders in childhood, such as autism and epileptic encephalopathy. However, few reports have demonstrated the cases carrying segmental deletions at the SCN2A locus for those with epileptic disorders. In this study, we report a 1.8-year-old boy, who presented with West syndrome in infancy and developed the sequelae of psychomotor delay and autism. Since whole-exome sequencing did not detect pathogenic mutations, we extensively searched for microdeletions and duplications by applying the eXome Hidden Markov Model (XHMM) for read depths of sequenced intervals. Using this approach, we identified a de novo deletion spanning the 1.1-Mb region of chromosome 2q24.3. We found that the deleted interval included the SCN2A and SCN3A loci. These data validate the utility of XHMM and support that SCN2A is involved in the pathogenic processes underlying epileptic encephalopathy in childhood.
Introduction
West syndrome (WS) is one of the well-known types of early onset epileptic encephalopathy, which is characterized by infantile onset of recurrent seizures and prominent interictal epileptiform discharges with frequent neurological comorbidity. A variety of mutations and copy number variations (CNVs) have been associated with this epileptic disorder. Among these, germline mutations in voltage-gated sodium channels (VGSCs) have been implicated in various neurological disorders. In particular, the chromosome 2q24.3 region has been drawing increasing attention since it harbors three VGSC genes: SCN1A, SCN2A, and SCN3A. We present the case of a one-year-old male with autistic features, psychomotor delay, and a history of WS. A de novo 1.1-Mb heterozygous deletion spanning the SCN2A and SCN3A genes was identified in this patient, demonstrating it as one of the genetic causes of WS and developmental problems.
Case report
The proband was born after 39 weeks of gestation to healthy nonconsanguineous parents. His birth weight was 2982 g (−0.04 SD) and the head circumference was 32.5 cm (−0.57 SD). Although he developed normally for the first 4 months, eye contact and facial expression disappeared at this age. Motor delay was evident at 9 months. He was referred to us at 10 months for recurrent episodes of head nodding and upward eye deviations occurring in clusters. Facial dysmorphisms of upslanted palpebral fissure, hypertelorism, and cupid's bow mouth were noted, with an absence of eye contact and smiles. Poor head control, generalized muscular hypotonia, stereotypic behavior, and dystonia-like involuntary movements were observed. Interictal electroencephalogram demonstrated a typical hypsarrhythmic pattern when sleeping and awake (Fig. 1A) . He was thus diagnosed with WS. Pyridoxine and valproate did not improve the seizure frequency. Intramuscular low-dose adrenocorticotropic hormone administered was effective, and subsequent seizure control was achieved with topiramate. Known etiologic factors for symptomatic WS were ruled out after laboratory tests including metabolic profiling. Intracranial MRI yielded normal findings (Fig. 1B) . Chromosomal analysis using G-banding revealed a normal male karyotype. Development was evaluated to be as low as 8 months at 21 months of age according to the Denver development screening test. He was diagnosed with autism spectrum disorders (ASD) using the Modified Checklist for Autism in ToddlersRevised.
Following written informed consent, genomic DNA was extracted from leukocytes of the patient and his parents. Whole-exome sequencing (WES) and variant calling were performed as previously described [1] . CNV analysis using the WES data was performed by eXome Hidden Markov Model (XHMM) algorithm. The deletion interval was further determined by analyzing the relative depth of coverage ratio (Nord's script) [1] . Quantitative real-time PCR (qPCR) was performed to validate the predicted CNVs (Supplementary method). Experimental protocols were approved by the Institutional Review Board of Yokohama City University School of Medicine, Japan.
Following WES, 95.8% of target coding sequences were covered by 10 or more reads. Because WES did not reveal any causative de novo point mutations in previously known epileptic encephalopathy-associated genes including ARX, KCNT1, KCNQ2, SCN1A, SCN2A, SCN8A, STXBP1, SPTAN1, GNAO1, GRIN1, FOXG1, QARS, EEF1A2, PIGA, CDKL5, SLC35A2, CASK, PCDH19, or MECP2, we hypothesized that the present case might carry pathogenic CNVs. Indeed, XHMM successfully detected a microdeletion encompassing a 1,102-kb region of chromosome 2q24.3 (GRch37/hg19; chr2: 165,349,365-166,451,795) (Fig. 1C) . Analysis of the relative coverage ratio depth using Nord's script against genes within or adjacent to the deleted interval revealed that the deletion contained FIGN, GRB14, COBLL1, SLC38A11, SCN3A, SCN2A, and part of CSRNP3 (Fig. 1D) . SCN1A gene located at the telomeric side of this region was not involved. qPCR analysis confirmed that the microdeletion spanning SCN3A and SCN2A had occurred de novo (Fig. 1E) .
Discussion
Chromosomal deletions involving the Sodium voltage-gated channels (SCN) gene cluster at 2q24.3 have been documented in patients with epilepsy [1] . Deletion of the SCN1A gene was perceived to be the dominant genetic factor in these cases, as loss-of-function SCN1A mutations are associated with severe epilepsy phenotypes. Three cases of SCN2A deletion without concomitant SCN1A involvement were reported previously [2] [3] [4] . Clinical symptoms and deletion ranges are summarized in Table 1 . Although all patients showed autistic features, neurodevelopmental disorders, and facial dysmorphism, only 1 patient exhibited infantile seizure of unknown type without electroencephalogram abnormalities [3] . This is the first report implicating a deletion of SCN2A and SCN3A as a probable genetic cause in a clearly defined WS case. SCN2A encodes the α-subunit of VGSCs (Na v 1.2), which are highly expressed in the brain at an early postnatal stage. SCN2A mutations have been associated with various neurodevelopmental disorders, including ASDs and intellectual disability. Earlier studies have shown that point mutations in SCN2A cause a variety of seizure phenotypes ranging from benign neonatal-infantile seizures to severe infantile-onset epilepsies, including Ohtahara syndrome, WS, and epilepsy of infancy with migrating focal seizures. Moreover, deletion of the SCN2A gene has been reported in ASDs, suggesting haploinsufficiency of SCN2A may promote the onset of autistic features. Clinical characteristics of the proband included autistic behavior, involuntary movement, and facial dysmorphism, consistent with previously reported 2q24.3 deletion cases.
Previous studies indicated that Na v 1.2 is predominantly expressed at terminals and initial segments of axons, playing essential roles in regulating both neuronal firing and inter-neuronal connectivity. SCN3A-encoded Nav1.3 exhibits a predominantly somato-dendritic localization and has properties that may cause neuronal hyper-responsiveness. SCN3A was thought to be insignificant in the neurobiology of epilepsy. However, a possible association of SCN3A variants and focal epilepsy owing to increased seizure susceptibility was reported in recent electrophysiological studies.
Given the intact copy number of SCN1A in this case, the SCN2A deletion might be sufficient to present a severely epileptic phenotype. Haploinsufficiency of SCN3A and other deleted genes or dual haploinsufficiency of SCN2A and SCN3A may lead to the syndromic phenotypes of WS, dysmorphism and ASDs as observed in our case. Future studies involving the functional interactions between SCN3A and SCN2A could be helpful. Collectively, our study provides new evidence that the CNV involving SCN2A plays a critical role in the pathogenic processes for both WS and ASDs. It also emphasizes XHMM as a powerful tool for identifying pathogenic CNVs in epileptic disorders.
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